Microbot Medical raises $25.2 million through investment options

HINGHAM, Mass. - Microbot Medical Inc. (NASDAQ:MBOT) announced Tuesday the first closing of its previously disclosed exercise of outstanding preferred investment options, raising approximately $25.2 million in gross proceeds. The medical device company, which has seen its stock surge over 205% year-to-date according to InvestingPro data, maintains a strong liquidity position with a current ratio of 12.06, indicating robust short-term financial health.

The medical device company completed the first tranche of a two-part offering, with investors exercising options to purchase 12,064,627 shares of common stock at prices ranging from $1.50 to $2.13 per share. In exchange, Microbot issued new unregistered short-term series J preferred investment options to these holders. InvestingPro analysis shows the stock trading at a Price-to-Book ratio of 5.93, suggesting premium valuation levels compared to peers.

A second closing, expected by October 15, 2025, could generate an additional $4 million through the exercise of options to purchase 1,924,488 shares at $2.10 per share, subject to customary closing conditions.

The newly issued series J options have an exercise price of $4.50 per share, will become exercisable six months after issuance, and will remain valid for two years thereafter. If fully exercised, these options could potentially provide Microbot with approximately $63 million in additional funding.

H.C. Wainwright & Co. served as the exclusive placement agent for the offering.

Microbot intends to use the proceeds for continued development, commercialization, and regulatory activities for its LIBERTY Robotic System, which the company describes as the first single-use, remotely operated robotic solution for endovascular procedures. Funds may also support potential acquisitions and expansion of applications from the company’s intellectual property portfolio.

The new series J preferred investment options were offered through a private placement exempt from Securities Act registration requirements. Microbot has agreed to file a registration statement with the SEC covering the resale of shares issuable upon exercise of these options.

Based on a press release statement, this financing represents a significant capital infusion for the medical device company as it continues its commercialization efforts. While the stock has recently experienced an 11% decline over the past week, InvestingPro subscribers can access 8 additional key insights about Microbot Medical’s financial health and market position. Get exclusive access to detailed analysis and Fair Value estimates to make more informed investment decisions.

In other recent news, Microbot Medical has received 510(k) clearance from the U.S. Food and Drug Administration for its LIBERTY Endovascular Robotic System. This clearance marks the system as the first FDA-approved, single-use, remotely operated robotic system for peripheral endovascular procedures, with commercialization in the U.S. expected in the fourth quarter of 2025. Following this development, H.C. Wainwright raised its price target for Microbot Medical from $9.00 to $12.00, maintaining a Buy rating on the company. Additionally, Microbot Medical announced the issuance of nearly 3 million shares through the exercise of various preferred investment options, raising approximately $5.9 million in gross proceeds. The company also plans to showcase the FDA-cleared LIBERTY System at the H.C. Wainwright Annual Investor Conference. In a related development, Harel Gadot, CEO of Microbot Medical, has been appointed as an independent director to the board of Brenmiller Energy. These recent developments highlight significant progress and strategic moves by Microbot Medical in the medical robotics sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.